Compare places
Two or three clusters, read side by side across sectors, research, companies, capital, infrastructure, government designations and UKIZ relevance. There is no score and no ranking: British clusters are different from one another, not better or worse than one another.
Choose up to three clusters
- London
- Cambridge
- Oxford
- Manchester
- Birmingham & the West Midlands
- Bristol & Bath
- Sheffield & Rotherham
- Leeds & West Yorkshire
- Liverpool City Region
- Newcastle & the North East
- Teesside & the Humber
- Edinburgh
- Glasgow & the Central Belt
- Belfast
- Cardiff & South Wales
- Southampton & Portsmouth
- Cornwall & Plymouth
- Nottingham & Derby
- Norwich & the East
Side by side
| Dimension | Leeds & West YorkshireYorkshire and the Humber | Sheffield & RotherhamYorkshire and the Humber | CambridgeEast of England |
|---|---|---|---|
| Sectors | Life Sciences, Digital Technologies, Financial Technology Supporting: Artificial Intelligence, Advanced Manufacturing, Creative Industries | Advanced Manufacturing, Advanced Materials Supporting: Clean Energy, Robotics & Autonomous Systems, Mobility & Transport Technology, Digital Technologies | Life Sciences, Semiconductors, Engineering Biology, Artificial Intelligence Supporting: Quantum Technologies, Advanced Materials, AgriTech & FoodTech, Digital Technologies |
| Research |
|
|
|
| Companies |
| Not recorded on the map. |
|
| Infrastructure | Not recorded on the map. Health data infrastructure, teaching hospitals and university research facilities. |
High Value Manufacturing Catapult centres, nuclear manufacturing facilities and industrial research factories. |
University and institute laboratories, genomics and biomedical campus facilities, and semiconductor design capability. |
| Capital | Financial services depth locally, but early-stage health technology capital remains limited. | Public co-investment, corporate partnership and asset finance rather than venture capital. | Specialist deep tech and life science funds, university-linked funds, and corporate partners; strong at seed, thinner at growth stage relative to demand. |
| Government programmes | No place-based designation recorded. | No place-based designation recorded. | No place-based designation recorded. |
| What exists | National health data organisations, medical technology, a large financial and professional services base and a research university with data and materials strength. | One of the strongest applied manufacturing research bases in Europe, covering machining, materials, nuclear manufacturing and factory-scale process development, working directly with industrial customers. | Extreme research density for its size: life sciences and genomics, semiconductor and processor IP, engineering biology and AI, with a mature spin-out culture and specialist investors who understand long timelines. |
| What's missing · UKIZ interpretation | A clear route for companies to work with health data at scale, and clinical adoption pathways that move faster than pilot projects. | Domestic demand. World-class process capability is often demonstrated for overseas primes, and local SMEs lack the capital to adopt what is proven a mile away. | Ownership retention. Discovery and early company formation work; the Series B onward stage frequently transfers ownership overseas. Laboratory and scale-up space, power and housing also constrain growth. |
| What could connect · UKIZ interpretation | Leeds health data capability connected to Manchester clinical research and to medical technology manufacturing, giving companies discovery, evidence and production in one region. | Applied manufacturing research connected to domestic customers — energy, defence, mobility and medical technology — with procurement used as the connector rather than grants. | Cambridge discovery connected to UK manufacturing and biomanufacturing capacity, and to later-stage domestic capital, so that value created here is realised here rather than acquired out of the country. |
| UKIZ relevance | Health data at population scale is a national asset. The proposed Manchester mission and Leeds capability are complementary rather than competing. | The research is world class; the domestic customer base for what it produces is thinner than it should be. The proposed Midlands and Teesside & Humber missions both depend on this capability. | Cambridge produces intellectual property at a rate few places match, and loses ownership of too much of it at Series B. The proposed Oxford–Cambridge zone concentrates on commercialisation and retention rather than on more discovery. |
| Last verified | 15 August 2026 | 15 August 2026 | 15 August 2026 |
Proposed by UKIZ · independent · not a government designation